Phospholipidosis induced by drugs with a cationic amphiphilic structure is a generalized condition in humans and animals that is characterized by an intracellular accumulation of phospholipids and the concurrent development of concentric lamellar bodies. The primary mechanism responsible for the development of phospholipidosis is an inhibition of lysosomal phospholipase activity by the drugs. While the biochemical and ultrastructural features of the condition have been well characterized, much less effort has been directed toward understanding whether the condition has adverse effects on the organism. While there are a few cationic amphiphilic drugs that have been reported to cause phospholipidosis in humans, the principal concern with this condition is in the pharmaceutical industry during preclinical testing. While this class of drugs should technically be referred to as cationic lipophilic, the term cationic amphiphilic is widely used and recognized in this field, and for this reason, the terminology cationic amphiphilic drugs (CADs) will be employed in this Minireview. The aim of this Minireview is to provide an evaluation of the state of knowledge on the functional consequences of CAD-induced phospholipidosis.
DrenckhahnD, Klein, Lüllmann-RauchR. Lysosomal alterations in cultured macrophages exposed to anorexigenic and psychotropic drugs. Lab Invest35: 116–123, 1976.
5.
JagelM, Lüllmann-RauchR. Lipidosis-like alterations in cultured macrophages exposed to local anaesthetics. Arch Toxicol55: 229–232, 1984.
6.
RubenZ, AndersonSN, KacewS. Changes in saccharide and phospholipid content associated with drug storage in cultured rabbit aorta muscle cells. Lab Invest64: 574–584, 1991.
7.
McCloudCM, BeardTL, KacewS, ReasorMJ. In vivo and in vitro reversibility of chlorphentermine-induced phospholipidosis in rat alveolar macrophages. Exp Mol Pathol62: 12–21, 1995.
8.
GlosterJ, HeathD, HasletonP, HarrisP. Effect of chlorphentermine on the lipids of rat lungs. Thorax31: 558–564, 1976.
9.
KarabelnikD, ZbindenG. Drug-induced foam cell reactions in rats. II. Chemical analysis of lipids stored in lungs and foam cells after treatment with chlorphentermine, 5-[p-(fluoren-9-ylidenemethyl)phenyl]-2-piperidineethanol(RMI 10.393) and 1-chloramitriptyline. Hoppe Seylers Z Physiol Chem356: 1151–1160, 1975.
10.
KacewS, ReasorMJ. Chlorphentermine-induced alterations in pulmonary phospholipid content in rats. Biochem Pharmacol32: 2683–2688, 1983.
11.
MartinWJII, StandingJE. Amiodarone pulmonary toxicity: Biochemical evidence for a cellular phospholipidosis in the bronchoalveolar lavage fluid of human subjects. J Pharmacol Exp Ther244: 774–779, 1988.
12.
ReasorMJ, OgleCL, KacewS. Amiodarone-induced pulmonary toxicity in rats: Biochemical and pharmacological characteristics. Toxicol Appl Pharmacol97: 124–133, 1989.
13.
SeilerKU, WassermannO. Drug-induced phospholipidosis. II. Alterations in the phospholipid pattern of organs from mice, rats and guinea pigs after chronic treatment with chlorphentermine. Naunyn Schmiedebergs Arch Pharmacol288: 261–268, 1975.
14.
ReasorMJ. Drug-induced lipidosis and the alveolar macrophage. Toxicology20: 1–33, 1981.
15.
ReasorMJ. Phospholipidosis in the alveolar macrophage induced by cationic amphiphilic drugs. Fed Proc43: 2578–2581, 1984.
16.
ReasorMJ. Role of the alveolar macrophage in the induction of pulmonary phospholipidosis: Pharmacologic and toxicologic considerations. In: HollingerMA, Ed. Current Topics in Pulmonary Pharmacology and Toxicology. New York: Elsevier Science, pp 43–7l, 1987.
17.
ReasorMJ. A review of the biology and toxicological implications of the induction of lysosomal lamellar bodies by drugs. Toxicol Appl Pharmacol97: 47–56, 1989.
18.
HostetlerKY. Molecular studies of the induction of cellular phospholipidosis by cationic amphiphilic drugs. Fed Proc43: 2582–2585, 1984.
19.
HrubenZ. Pulmonary and generalized lysosomal storage induced by amphiphilic drugs. Environ Health Perspec55: 53–76, 1984.
20.
KacewS. Role of age in amphiphilic drug-induced pulmonary morphological and metabolic responses. Fed Proc43: 2592–2596, 1984.
HeinL, Lüllmann-RauchR, MohrK. Human accumulation potential of xenobiotics: Potential of catamphiphilic drugs to promote their accumulation via inducing lipidosis or mucopolysaccharidosis. Xenobiotica20: 1259–1267, 1990.
23.
HookGER. Alveolar proteinosis and phospholipidoses of the lungs. Toxicol Pathol19: 482–513, 1991.
24.
RubenZ, RorigKJ, KacewS. Perspectives on intracellular storage and transport of cationic-lipophilic drugs. Proc Soc Exp Biol Med203: 140–149, 1993.
XiaZ, YingG, HanssonAL, KarlssonH, XieY, BergstrandA, DePierreJW, NassbergerL. Antidepressant-induced lipidosis with special reference to tricyclic compounds. Prog Neurobiol60: 510–512, 2000.
27.
NelsonAA, FitzhughOG. Chloroquine: Pathological changes observed in rats which for two years had been fed various proportions. Arch Pathol45: 454–462, 1948.
28.
FrankenG, LuällmannH, SiegfriedtA. The occurrence of huge cells in pulmonary alveoli of rats treated by an anorexic drug. Arzneimit-telforschung20: 417, 1970.
Luällmann-RauchR, ReilGH. Chlorphentermine-induced lipidosis-like ultrastructural alterations in lungs and adrenal glands of several species. Toxicol Appl Pharmacol30: 408–421, 1974.
35.
KacewS. Alterations in newborn and adult rat lung morphology and phospholipid levels after chlorcyclizine or chlorphentermine treatment. Toxicol Appl Pharmacol65: 100–108, 1982.
36.
ReasorMJ, OgleCL, Kacew. Amiodarone-induced phospholipidosis in rat alveolar macrophages. Am Rev Respir Dis137: 510–518, 1988.
37.
KacewS, RubenZ, McConnellRF. Strain as a determinant factor in the differential responsiveness of rats to chemicals. Toxicol Pathol23: 701–714, 1995.
38.
KacewS, FestingMF. Role of rat strain in differential sensitivity to pharmaceutical agents and naturally occurring substances. J Toxicol Environ Health47: 1–30, 1996.
ReasorMJ, McCloudCM, BeardTL, EbertDC, KacewS, GardnerMF, AldernKA, HostetlerKY. Comparative evaluation of amiodarone-induced phospholipidosis and drug accumulation in Fischer-344 and Sprague-Dawley rats. Toxicology106: 139–147, 1996.
41.
KuboM, HostetlerKY. Mechanism of cationic amphiphilic drug inhibition of purified lysosomal phospholipase Al. Biochemisry24: 6515–6520, 1985.
42.
MaJYC, MaJKH, WeberKC. Fluorescence studies of the binding of amphiphilic amines with phospholipids. J Lipid Res26: 735–744, 1985.
43.
PappuA, HostetlerKY. Effect of cationic amphiphilic drugs on the hydrolysis of acidic and neutral phospholipids by liver lysosomal phospholipase A. Biochem Pharmacol33: 1639–1644, 1984.
44.
KacewS, NarbaitzR, DubasTC. Biochemical and morphologic investigation of the influence of chlorphentermine and subsequent withdrawal on newborn rat lung. Toxicol Appl Pharmacol47: 185–191, 1979.
45.
ReasorMJ, CastranovaV. Recovery from chlorphentermine-induced phospholipidosis in rat alveolar macrophages. I. Biochemical and cellular features. Exp Mol Pathol35: 359–369, 1981.
46.
ReasorMJ, WalkerER. Recovery from chlorphentermine-induced phospholipidosis in rat alveolar macrophages. II. Morphological features. Exp Mol Pathol35: 370–399, 1981.
SunEL, PetrellaDK, McCloudCM, CramerCT, ReasorMJ, UlrichRG. Amiodarone-induced cytoplasmic lamellar body formation in cultured primary rat and human hepatocytes: Relationship to cell function and cytotoxicity. In Vitro Toxicol10: 459–470, 1997.
54.
SarmaJSM, PeiH, VenkataramanK. Role of oxidative stress in amiodarone-induced toxicity. J Cardiovasc Pharmacol Ther2: 53–60, 1997.
55.
WilsonBD, ClarksonCE, LippmannML. Amiodarone causes decreased cell-mediated immune responses and inhibits the phospholipase C signaling pathway. Lung170: 137–148, 1993.
56.
SauersU, WierdaD, WalkerER, ReasorMJ. Morphological and functional changes in mouse splenic lymphocytes following in vivo and in vitro exposure to chlorphentermine. J Immunopharmacol8: 611–631, 1986.
57.
XiaZ, DePierreJW, NassbergerL. Tricyclic antidepressants inhibit IL-6, IL-1β and TNF-α release in human blood monocytes and IL-2 and interferon-γ in T cells. Immunopharmacology34: 27–37, 1996.
58.
RubenZ, DoddDC, RorigKJ, AndersonSN. Disobutamide: A model agent for investigating intracellular drug storage. Toxicol Appl Pharmacol97: 57–71, 1989.
59.
DrenckhahnD, Lullmann-RauchR. Lens opacities associated with lipidosis-like ultrastructural alterations in rats treated with chloroquine, chlorphentermine, or iprindole. Exp Eye Res24: 621–632, 1977.
60.
WeissJN, WeinbergRS, RegelsonW. Keratopathy after oral adminstration of tilorone hydrochloride. Am J Ophthalmol89: 46–53, 1980.
AntoniniJM, McCloudCM, ReasorMJ. Acute silica toxicity: Attenuation by amiodarone-induced pulmonary phospholipidosis. Environ Health Perspec102: 327–378, 1994.
63.
BlakeTL, DiMatteoM, AntoniniJM, McCloudCM, ReasorMJ. Subchronic pulmonary inflammation and fibrosis induced by silica in rates are attenuated by amiodarone. Exp Lung Res22: 113–131, 1996.
64.
HastingsCEJr., DeNicolaDB, RebarAH, TurekJJ, BomGS, KesslerWV. The effect of chlorphentermine pretreatment on the toxicity of nitrogen dioxide. Fundam Appl Toxicol9: 69–81, 1987.
KacewS. Cationic amphiphilic drug-induced renal cortical lyososomal phospholipidosis: An in vivo comparative study with gentamicin and chlorphentermine. Toxicol Appl Pharmacol91: 469–476, 1987.
